Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alex Iukuridze"'
Autor:
Jessica M. Scott, Lee W. Jones, Stephen J. Forman, F. Lennie Wong, Jack Ji Xie, Meisi Xiao, Saro H. Armenian, Sean Lee, Kristen Mascarenhas, Jennifer Berano Teh, Howard A. Chang, Brandyn Lee, Alex Iukuridze, Ryotaro Nakamura
Publikováno v:
JNCI: Journal of the National Cancer Institute. 111:837-844
Background High intensity treatments such as hematopoietic cell transplantation (HCT) can be curative for patients with hematologic malignancies, but this needs to be balanced by the high risk of nonrelapse mortality (NRM) during the first 2 years af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee14142dd7ffb9d61ffa1f7cd7de3a0
https://doi.org/10.1093/jnci/djy231
https://doi.org/10.1093/jnci/djy231
Autor:
Teresa Cabrera Vera, Kyuwan Lee, Elizabeth Budde, Leslie Popplewell, Jennifer Berano Teh, Justin Ramos, Stephen J. Forman, Andrew S. Artz, Tanya Siddiqi, Alex Iukuridze, Geoffrey Shouse, Alex F. Herrera, Saro H. Armenian, Rusha Bhandari, Lennie Wong
Publikováno v:
Blood. 138:2502-2502
Introduction: Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) or other B-cell lymphomas. However, the potent anti-lymphoma effect of CAR-T is balan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fe7fb4e79b731db67bdb0bbd75cb092
https://doi.org/10.1182/blood-2021-149784
https://doi.org/10.1182/blood-2021-149784
Autor:
Lennie Wong, Alex Iukuridze, Farah Abdulla, Liezl Atencio, Alan C. Geller, Saro H. Armenian, Meagan Echevarria, Jennifer Berano Teh, Ryotaro Nakamura, Badri Modi, Alicia Gonzales, Kelly Peng, Stephen J. Forman, Heeyoung Kim
Publikováno v:
Blood. 134:2011-2011
Introduction: Hematopoietic cell transplantation (HCT)-related factors, such as total body irradiation (TBI) used for conditioning, graft-versus-host disease (GvHD), and prolonged exposure to calcineurin-inhibitors, can result in high risk for subseq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::858ca8a85fe74734f87f0c4da83a5340
https://doi.org/10.1182/blood-2019-124993
https://doi.org/10.1182/blood-2019-124993
Autor:
Sandra Xu, Jasmine Zain, Meisi Xiao, Lee Brandyn, Lee W. Jones, Stephen J. Forman, Kristen Mascarenhas, Ryotaro Nakamura, F. Lennie Wong, Leslie Popplewell, Thomas P. Slavin, Jeannine S. McCune, Jessica M. Scott, Nicholas Rosen, Saro H. Armenian, Alex Iukuridze, Jennifer Berano Teh, Robert W. Chen
Publikováno v:
Blood. 132:620-620
Introduction: High intensity treatments such as autologous hematopoietic cell transplantation (HCT) can be curative for patients with relapsed/refractory lymphoma (Hodgkin [HL], non-Hodgkin [NHL]), but this needs to be balanced by the risk of non-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3035c4bbab521929fce54353235ac03
https://doi.org/10.1182/blood-2018-99-113689
https://doi.org/10.1182/blood-2018-99-113689